- Home
- TRAW vs MRM Comparison
TRAW vs MRM Comparison
Compare TRAW & MRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRAW
- MRM
- Stock Information
- Founded
- TRAW 1998
- MRM 2000
- Country
- TRAW United States
- MRM Japan
- Employees
- TRAW N/A
- MRM N/A
- Industry
- TRAW
- MRM Other Consumer Services
- Sector
- TRAW
- MRM Consumer Discretionary
- Exchange
- TRAW NYSE
- MRM Nasdaq
- Market Cap
- TRAW 15.0M
- MRM 12.2M
- IPO Year
- TRAW 2013
- MRM 2020
- Fundamental
- Price
- TRAW $5.54
- MRM $2.51
- Analyst Decision
- TRAW
- MRM
- Analyst Count
- TRAW 0
- MRM 0
- Target Price
- TRAW N/A
- MRM N/A
- AVG Volume (30 Days)
- TRAW 9.7K
- MRM 11.0K
- Earning Date
- TRAW 11-20-2024
- MRM 12-30-2022
- Dividend Yield
- TRAW N/A
- MRM N/A
- EPS Growth
- TRAW N/A
- MRM N/A
- EPS
- TRAW N/A
- MRM 0.16
- Revenue
- TRAW $226,000.00
- MRM $48,438,179.00
- Revenue This Year
- TRAW $2.90
- MRM N/A
- Revenue Next Year
- TRAW N/A
- MRM N/A
- P/E Ratio
- TRAW N/A
- MRM $16.64
- Revenue Growth
- TRAW N/A
- MRM N/A
- 52 Week Low
- TRAW $4.44
- MRM $2.27
- 52 Week High
- TRAW $27.50
- MRM $8.39
- Technical
- Relative Strength Index (RSI)
- TRAW 52.69
- MRM 42.33
- Support Level
- TRAW $4.92
- MRM $2.42
- Resistance Level
- TRAW $5.96
- MRM $3.07
- Average True Range (ATR)
- TRAW 0.28
- MRM 0.27
- MACD
- TRAW 0.17
- MRM 0.00
- Stochastic Oscillator
- TRAW 61.82
- MRM 31.00
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.